OncoMatch/Clinical Trials/NCT06176885
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Is NCT06176885 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab for colorectal cancer.
Treatment: Camrelizumab — The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are: 1. To explore the efficacy and safety of this treatment mode 2. Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: KRAS wild-type
Left colon cancer with wild-type rat sarcoma virus gene (RAS)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
The patient had received radiation therapy ... within 4 weeks before treatment
Cannot have received: surgery
The patient had received ... surgery ... within 4 weeks before treatment
Cannot have received: chemotherapy
The patient had received ... chemotherapy ... within 4 weeks before treatment
Cannot have received: immunotherapy
The patient had received ... immune ... therapy ... within 4 weeks before treatment
Cannot have received: molecular-targeted therapy
The patient had received ... molecular-targeted therapy ... within 4 weeks before treatment
Cannot have received: investigational drug
The patient had received ... other investigational drugs within 4 weeks before treatment
Cannot have received: anti-vascular small molecule targeted drug (Fruquintinib)
She had previously received anti-vascular small molecule targeted drug therapy, such as Fruquintinib
Cannot have received: irinotecan-based chemotherapy
Prior treatment with an irinotecan-based chemotherapy regimen
Lab requirements
Blood counts
Blood testing (not corrected with granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 7 days prior to laboratory testing if not transfused within 14 days)
Blood testing (not corrected with granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 7 days prior to laboratory testing if not transfused within 14 days)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify